F2G Ltd clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   COCCIMETRICS · Measures for Endpoint Derivation · Progressive or…COCCIMETRICS · Measures for Endpoint Derivation · Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care

   Primary endpoint(s) modified

   F2G Ltd·Phase 2· NCT07712484· Registry history of NCT07712484 on ClinicalTrials.gov (opens the registry)

   Updated Sep 22, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.